Coexisting or Underlying Risk Factors of Hepatic Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplant Recipients Receiving Prophylaxis

Unit of Pediatric Hematopoietic Stem Cell Transplantation, Ihsan Dogramaci Children's Hospital, Hacettepe University Medical Faculty, Ankara, Turkey.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 10/2013; 11(5):440-446. DOI: 10.6002/ect.2012.0265
Source: PubMed


To evaluate the characteristics of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients, and their effect as a prophylactic regimen on severity and outcome.
This study included 204 allogeneic hematopoietic stem cell transplants performed on 187 children whose data retrospectively described the risk factors, prophylaxis, and treatment modalities of veno-occlusive disease. A prophylactic regimen composed of enoxaparin versus ursodeoxycholic acid and vitamin E was given to 167 of 204 patients.
Veno-occlusive disease developed in 22 patients (10.8%). Nineteen patients experienced veno-occlusive disease despite this prophylactic regimen. The prophylaxis seemed ineffective in preventing veno-occlusive disease (P = .657). Regarding risk factors, oral busulphan use, liposomal amphotericin B vancomycin treatment, and total parenteral nutrition were associated with an increased risk of veno-occlusive disease. Conversely, renal impairment also was associated with increased mortality in patients with veno-occlusive disease. The mortality rate in the first 100 days after a hematopoietic stem cell transplant was higher in the patients with veno-occlusive disease than it was in those without the disease.
Our prophylactic regimen may have played a role in the fairly low incidence of veno-occlusive disease in a pediatric population with high-risk features.

27 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatic sinusoidal obstruction syndrome (SOS) is an obliterative venulitis of the terminal hepatic venules, which in its more severe forms imparts a high risk of mortality. SOS, also known as veno-occlusive disease (VOD), occurs as a result of cytoreductive therapy prior to hematopoietic stem cell transplantation (HSCT), following oxaliplatin-containing adjuvant or neoadjuvant chemotherapy for colorectal carcinoma metastatic to the liver and treated by partial hepatectomy, in patients taking pyrrolizidine alkaloid-containing herbal remedies, and in other particular settings such as the autosomal recessive condition of veno-occlusive disease with immunodeficiency (VODI). A central pathogenic event is toxic destruction of hepatic sinusoidal endothelial cells (SEC), with sloughing and downstream occlusion of terminal hepatic venules. Contributing factors are SEC glutathione depletion, nitric oxide depletion, increased intrahepatic expression of matrix metalloproteinases and vascular endothelial growth factor (VEGF), and activation of clotting factors. The clinical presentation of SOS includes jaundice, development of right upper-quadrant pain and tender hepatomegaly, ascites, and unexplained weight gain. Owing to the potentially critical condition of these patients, transjugular biopsy may be the preferred route for liver biopsy to exclude other potential causes of liver dysfunction and to establish a diagnosis of SOS. Treatment includes rigorous fluid management so as to avoid excessive fluid overload while avoiding too rapid diuresis or pericentesis, potential use of pharmaceutics such as defibrotide, coagulolytic agents, or methylprednisolone, and liver transplantation. Proposed strategies for prevention and prophylaxis include reduced-intensity conditioning radiation for HSCT, treatment with ursodeoxycholic acid, and inclusion of bevacizumab with oxaliplatin-based chemotherapeutic regimes. While significant progress has been made in understanding the pathogenesis of SOS and in mitigating against its adverse outcomes, this condition remains a serious complication of a selective group of medical treatments.
    Journal of Clinical and Experimental Hepatology 12/2014; 4(4):332-46. DOI:10.1016/j.jceh.2014.10.002
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Biocompatible and biodegradable liposome nanomedicine are finding large-scale application in delivery of drugs, RNA, antisense oligonucleotides, DNA, plasmids carrying gene, antioxidants to targeted sites for diagnosis, and treatment at cellular and molecular level of disease both in human and livestock. Conventional drug delivery system suffers from the disadvantage of narrow therapeutic index, poor serum solubility, and nonspecific target effects. Circumventing this problem, liposome drug nanoparticles are designed with the advantage of enhanced permeability, retention effect, selective targeted delivery, stimuli-induced release that can evade the host defense system, cross the blood– brain barrier, thus conferring, synergetic effects, small interfering RNA (siRNA) co-delivery, multimodality therapies, and oral delivery of therapeutics at disease sites. Liposomes with diverse range of modifications are being designed to generate improvised medicine delivery systems. Immuno-liposomes, linked with antibodies are promising tools for targeted drug delivery to specific cancer cells. In the recent times several anti-cancer agents in nanodelivery systems are under preclinical and clinical studies. Lipid-based liposomal delivery systems of self-amplifying RNA vaccines are showing promising effects. Globally research is being carried out in generating liposomes with higher compatibility within the biological system in targeting a wide array of diseases including cancer, overcoming multidrug resistance, inflammatory diseases, thrombosis, psoriasis, muscular dystrophy, spinal cord injury, neurologic diseases, diabetes, parasite induced diseases, and cardiovascular diseases. In this chapter, we have summarized the recent developments in the field of liposomal nanomedicine under the following topics: (i) diverse formulation of liposome nanomedicine, (ii) agents delivered by nanoliposomes, (iii) nanoliposomes and their application as vaccines, (iv) liposomal nanomedicine in targeting diseases, (v) liposomal nanomedicine and stem cell therapy, (vi) their application in preclinical and clinical studies, risks, and (vii) safety issues.
    Nanoparticles’ Promises and Risks,, 01/2015: chapter chapter 9: pages 167-210; Springer International Publishing Switzerland 2015.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Busulfan (Bu) is widely used in conditioning regimens for infants undergoing allogeneic hematopoietic progenitor cell transplant (HPCT), but the best approach to administer Bu in this population is still unknown. Here we report a single center experience of the use of a test dose to guide dose adjustment of intravenous (IV) Bu therapy in infants. Between 2004 and 2013, 33 infants less than 1 year of age with non-malignant conditions received allogeneic peripheral blood or cord blood HPCT after a reduced-intensity conditioning (RIC) regimen consisting of fludarabine, anti-thymocyte globulin and 2 single daily doses of IV Bu. Pharmacokinetic results of a test dose of IV Bu (0.8 mg/kg) were used to determine the dose of 2 single daily IV Bu regimen doses, adjusted to target an AUC of 4000 μMol*min per day in a first cohort (n=12) and 5000 μMol*min in a second cohort (n=21). The mean Bu clearance in our infant patients was found to be 3.67 ± 1.03 ml/min/kg, and the test dose clearance was highly predictive of the regimen dose clearance. The mean AUC achieved after the first single daily regimen dose was 3951 ± 1239 in the AUC 4000 cohort and 4884 ± 766 for the AUC 5000 cohort. No patient in either cohort developed hepatic sinusoidal obstructive syndrome or seizures attributable to Bu. Primary graft failure occurred in 4 patients, and secondary graft failure in 3, predominantly in the AUC 4000 cohort (6 of 7). Among the engrafted patients (n=28), 16 achieved full donor chimerism and 9 patients attained stable mixed chimerism. Overall survival of patients at 6 years post-transplant were 59.5% for the AUC 4000 cohort and 85.4% for the AUC 5000 cohort, with primary graft failure in the first cohort being a major contributor to morbidity. Logistic regression analysis showed that the risk of graft failure increased significantly if cord blood HPC was used or if total Bu exposure was below 4000 μMol*min per day for 2 days. The difference in clinical outcomes between the 2 cohorts supports the conclusion that targeting a higher Bu AUC of 5000 μMol*min per day for 2 days improves donor engraftment in infants with non-malignant conditions undergoing RIC HPCT without increasing toxicity. Measuring IV Bu PK using a test dose allows timely adjustment of single daily regimen doses and optimization of total Bu exposure, resulting in an effective and safe regimen for these infants. Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 05/2015; 21(9). DOI:10.1016/j.bbmt.2015.05.017 · 3.40 Impact Factor